Sign Out
GynProgest Vaginal 200 mg Capsules may interfere with the effects of bromocriptine and may raise the plasma concentration of ciclosporin. GynProgest Vaginal 200 mg Capsules may affect the results of laboratory tests of hepatic and/or endocrine functions.
Metabolism of GynProgest Vaginal 200mg Capsules is accelerated by rifamycin medicines (such as rifampicin) and antibacterial agents.
The metabolism of progesterone by human liver microsomes was inhibited by ketoconazole (IC50 <0.1 μM). Ketoconazole is a known inhibitor of cytochrome P450 3A4. These data therefore suggest that ketoconazole may increase the bioavailability of progesterone. The clinical relevance of the in vitro findings is unknown.
